Efficacy of EMDR Versus CBT for Post-Traumatic Stress Disorder in Pakistan
Efficacy of Eye Movement Desensitization and Reprocessing Versus Cognitive Behavioral Therapy for Post-Traumatic Stress Disorder and Comorbid Disorders in Pakistan: A Full-Fledged Randomized Controlled Trial
This randomized controlled trial compares Eye Movement Desensitization and Reprocessing (EMDR) therapy with Cognitive Behavioral Therapy (CBT) for the treatment of post-traumatic stress disorder (PTSD) in Pakistan. The study examines whether EMDR is at least as effective as CBT in reducing PTSD symptoms over time. It also assesses changes in symptoms of depression and anxiety that commonly occur alongside PTSD. Participants are randomly assigned to receive either EMDR or CBT, and their symptoms are assessed at different stages of treatment and follow-up.
調査の概要
状態
条件
詳細な説明
This study is a multi-center, single-blind, two-group randomized controlled trial designed to compare Eye Movement Desensitization and Reprocessing (EMDR) therapy with Cognitive Behavioral Therapy (CBT) for the treatment of post-traumatic stress disorder (PTSD) and associated symptoms of depression and anxiety.
The study is conducted in sequential phases. During the initial phase, the psychometric properties of the assessment measures are examined and treatment fidelity is evaluated to determine whether EMDR and CBT are delivered consistently and in accordance with their respective treatment protocols. The subsequent phase focuses on the comparative clinical effectiveness of EMDR and CBT.
Eligible participants with PTSD are randomly allocated to either the EMDR or CBT treatment condition using a covariate-adaptive stratified randomization procedure with a 1:1 allocation ratio. Treatment is delivered face-to-face by clinical psychologists trained in the respective psychotherapeutic approaches. The number of treatment sessions varies according to participants' clinical needs and symptom severity.
The primary objective is to examine whether EMDR is non-inferior to CBT in reducing PTSD symptoms. Additional objectives are to examine changes in PTSD symptoms over the course of treatment and follow-up, assess changes in associated depressive and anxiety symptoms, and explore the relationship between changes in PTSD symptoms and changes in these comorbid symptoms.
PTSD symptoms are assessed using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). Depressive symptoms are assessed using the Hamilton Depression Rating Scale (HDRS), and anxiety symptoms are assessed using the State-Trait Anxiety Inventory (STAI). Assessments are conducted at baseline, during treatment, at the end of treatment, and at follow-up.
Treatment fidelity is also evaluated by assessing therapists' adherence to the EMDR and CBT protocols and their competence in delivering the interventions.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Islamabad、パキスタン、4400
- Dr Farzana Bashir Clinic, Gulberg Green Office# G-67, Opal Sqaure, Islamabad (Wellness Clinic )
-
Peshawar、パキスタン、25000
- Paraplegic Center Peshawar
-
Peshawar、パキスタン、25000
- Psychiatry Unit & Rehabilitation Center, Lady Reading Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Aged 15 to 60 years.
- Confirmed diagnosis of post-traumatic stress disorder (PTSD), with PTSD identified as the primary clinical condition.
- Associated symptoms of depression and anxiety at screening.
- Able to participate in face-to-face psychotherapy and perform the basic eye and hand movements required for the treatment procedures.
- Able to provide informed consent and communicate sufficiently to participate meaningfully in assessment and psychotherapy.
Exclusion Criteria:
- Younger than 15 years or older than 60 years.
- Significant limitations in eye or hand movement, or inability to perform the basic movements required for participation in the treatment procedures.
- Prolonged unconsciousness or otherwise unable to maintain sufficient consciousness to participate meaningfully in assessment or psychotherapy.
- Does not meet the screening criteria for PTSD, or PTSD is not the primary clinical condition.
- Severe intellectual impairment that substantially limits the ability to understand, communicate, or participate in the assessment and psychotherapy procedures.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Eye Movement Desensitization and Reprocessing (EMDR) Therapy
Participants assigned to this arm received face-to-face Eye Movement Desensitization and Reprocessing (EMDR) therapy delivered by clinical psychologists trained in EMDR. Treatment followed an eight-stage EMDR protocol for PTSD, with culturally adapted procedures used where appropriate. The number of sessions varied according to symptom severity and clinical need, generally ranging from 6 to 14 sessions, typically delivered once per week. PTSD, depressive, and anxiety symptoms were assessed at baseline, during treatment, at the end of treatment, and at follow-up |
Eye Movement Desensitization and Reprocessing (EMDR) therapy was delivered face-to-face by clinical psychologists trained and certified in EMDR. Treatment followed an eight-stage EMDR protocol for post-traumatic stress disorder (PTSD), incorporating culturally adapted procedures where appropriate for the Pakistani clinical context. Treatment included history-taking and treatment planning, preparation, assessment, desensitization using bilateral stimulation, installation of adaptive cognitions, body scan, closure, and reevaluation. The number of sessions was determined according to participants' symptom severity and clinical needs and generally ranged from 6 to 14 sessions, typically delivered once per week. |
|
アクティブコンパレータ:Cognitive Behavioral Therapy (CBT)
Participants assigned to this arm received face-to-face Cognitive Behavioral Therapy (CBT) delivered by clinical psychologists trained in CBT. Treatment followed a structured trauma-focused CBT protocol, with culturally adapted procedures used where appropriate. The number of sessions varied according to symptom severity and clinical need, generally ranging from 6 to 14 sessions, typically delivered once per week. PTSD, depressive, and anxiety symptoms were assessed at baseline, during treatment, at the end of treatment, and at follow-up. |
Cognitive Behavioral Therapy (CBT) was delivered face-to-face by clinical psychologists trained and certified in CBT. Treatment followed a structured trauma-focused CBT protocol for post-traumatic stress disorder (PTSD), with culturally adapted procedures used where appropriate for the Pakistani clinical context. Treatment included assessment and engagement, psychoeducation, relaxation, affective modulation, cognitive coping and restructuring, trauma narrative work, exposure-based procedures, caregiver involvement where appropriate, and enhancement of safety. The number of sessions was determined according to participants' symptom severity and clinical needs and generally ranged from 6 to 14 sessions, typically delivered once per week. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Post-traumatic stress disorder symptoms
時間枠:Baseline (before treatment), mid-treatment (approximately halfway through the treatment course), end of treatment (following completion of treatment), and follow-up (approximately 1 to 3 months after treatment completion)
|
PTSD symptom severity was assessed using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). CAPS-5 scores were collected at baseline, during treatment, at the end of treatment, and at follow-up to evaluate changes in PTSD symptoms over time and to compare the EMDR and CBT treatment groups. |
Baseline (before treatment), mid-treatment (approximately halfway through the treatment course), end of treatment (following completion of treatment), and follow-up (approximately 1 to 3 months after treatment completion)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Depressive symptoms
時間枠:Baseline (before treatment), mid-treatment (approximately halfway through the treatment course), end of treatment (following completion of treatment), and follow-up (approximately 1 to 3 months after treatment completion)
|
Depressive symptoms were assessed using the Hamilton Depression Rating Scale (HDRS). Scores were collected at baseline, during treatment, at the end of treatment, and at follow-up to evaluate changes in depressive symptoms over time in the EMDR and CBT treatment groups. |
Baseline (before treatment), mid-treatment (approximately halfway through the treatment course), end of treatment (following completion of treatment), and follow-up (approximately 1 to 3 months after treatment completion)
|
|
Anxiety symptoms
時間枠:Baseline (before treatment), mid-treatment (approximately halfway through the treatment course), end of treatment (following completion of treatment), and follow-up (approximately 1 to 3 months after treatment completion)
|
Anxiety symptoms were assessed using the State-Trait Anxiety Inventory (STAI). Scores were collected at baseline, during treatment, at the end of treatment, and at follow-up to evaluate changes in anxiety symptoms over time in the EMDR and CBT treatment groups. |
Baseline (before treatment), mid-treatment (approximately halfway through the treatment course), end of treatment (following completion of treatment), and follow-up (approximately 1 to 3 months after treatment completion)
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 111
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data (IPD) will not be shared. The study involves sensitive mental health, trauma-related, and clinical information, and the consent and ethical framework for the study did not provide for public or external sharing of individual-level participant data. Aggregate study findings may be reported in publications and other research outputs.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。